argenx NV operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares argenx NV with three other
companies in this sector in Belgium:
Thrombogenics Nv
(2017
sales of 9.06 million Euro [US$11.06 million]
),
MDxHealth S.A.
(35.56 million Euro [US$43.42 million]
), and
Ablynx N.V.
(55.53 million Euro [US$67.80 million]
of which 100%
was Nanobodies).
Sales Analysis.
argenx NV reported sales of 36.42 million Euro (US$44.46 million)
for the
year ending
December of 2017.
This
represents
an
increase of 147.5%
versus 2016, when the company's sales were 14.71 million Euro.
Sales at argenx NV have increased during each of the previous five years
(and since 2012, sales have increased a total of 2,106%).